(Q60368051)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126241%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126241%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126241%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Kenneth J. Pienta

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126241%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

2

Kenneth J. Pienta

0 references

author name string

David C. Smith

series ordinal

1

0 references

publication date

1 May 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126241%20AND%20SRC:MED&resulttype=core&format=json

Urologic Clinics of North America

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126241%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126241%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126241%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

433-437

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126241%20AND%20SRC:MED&resulttype=core&format=json

Analysis of survival by tumor response.

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970390-6

7 January 2021

Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970390-6

7 January 2021

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970390-6

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970390-6

7 January 2021

Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970390-6

7 January 2021

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970390-6

7 January 2021

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970390-6

7 January 2021

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970390-6

7 January 2021

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970390-6

7 January 2021

Suramin: an anticancer drug with a unique mechanism of action.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970390-6

7 January 2021

10.1016/S0094-0143(05)70390-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9126241%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference